JP2015510393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510393A5 JP2015510393A5 JP2014553578A JP2014553578A JP2015510393A5 JP 2015510393 A5 JP2015510393 A5 JP 2015510393A5 JP 2014553578 A JP2014553578 A JP 2014553578A JP 2014553578 A JP2014553578 A JP 2014553578A JP 2015510393 A5 JP2015510393 A5 JP 2015510393A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- peptide according
- agent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 150000001413 amino acids Chemical group 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 108030004415 Non-specific serine/threonine protein kinases Proteins 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- 108060006706 SRC Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101150107888 AKT2 gene Proteins 0.000 claims 1
- 101150051155 Akt3 gene Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 108091006116 chimeric peptides Proteins 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012900259 | 2012-01-24 | ||
| AU2012900259A AU2012900259A0 (en) | 2012-01-24 | Agents for use in cancer therapy | |
| AU2012904368 | 2012-10-06 | ||
| AU2012904368A AU2012904368A0 (en) | 2012-10-06 | Anti-cancer peptides | |
| PCT/AU2013/000045 WO2013110120A1 (en) | 2012-01-24 | 2013-01-24 | Peptide agents for cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510393A JP2015510393A (ja) | 2015-04-09 |
| JP2015510393A5 true JP2015510393A5 (enExample) | 2016-03-17 |
| JP6249447B2 JP6249447B2 (ja) | 2017-12-20 |
Family
ID=48872819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553578A Expired - Fee Related JP6249447B2 (ja) | 2012-01-24 | 2013-01-24 | 癌治療用ペプチド剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9403877B2 (enExample) |
| EP (1) | EP2807180B1 (enExample) |
| JP (1) | JP6249447B2 (enExample) |
| CN (1) | CN104271590B (enExample) |
| AU (1) | AU2013202137B2 (enExample) |
| CA (1) | CA2862485C (enExample) |
| WO (1) | WO2013110120A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101644982B1 (ko) * | 2015-07-23 | 2016-08-02 | 주식회사 엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
| CN105294839A (zh) * | 2015-10-28 | 2016-02-03 | 上海大学 | 对新生血管形成有阻断功能的多肽化合物及其应用 |
| CN106167513A (zh) * | 2016-07-09 | 2016-11-30 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
| CN105936642A (zh) * | 2016-07-09 | 2016-09-14 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
| CN106146620A (zh) * | 2016-07-09 | 2016-11-23 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
| CN105936643A (zh) * | 2016-07-09 | 2016-09-14 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
| CN106084012A (zh) * | 2016-07-09 | 2016-11-09 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| CN111094324B (zh) * | 2018-03-14 | 2023-10-10 | 武汉博威德生物技术有限公司 | 一种溶瘤病毒、合成dna序列及其应用 |
| CN112399970B (zh) * | 2018-05-15 | 2025-12-12 | 英特肽治疗有限公司 | 肽活化剂 |
| EP3794015A4 (en) * | 2018-05-15 | 2022-03-30 | InterK Peptide Therapeutics Limited | ACTIVATING AGENT |
| WO2020107079A1 (en) * | 2018-11-30 | 2020-06-04 | Interk Peptide Therapeutics Limited | Polypeptides and methods for improving skin conditions |
| CN110893236A (zh) * | 2019-10-09 | 2020-03-20 | 中山大学 | 溶酶体靶向的抗体药物偶联物及其应用 |
| CN112646018B (zh) * | 2021-01-25 | 2023-04-28 | 井冈山大学 | 一种抑制肿瘤细胞增殖和转移的生物活性肽及其应用 |
| JP2024532850A (ja) * | 2021-08-20 | 2024-09-10 | インテルク ペプチド セラピューティクス リミテッド | がん及びがん療法に関連する自己免疫を含む、自己免疫を処置するための組成物及び方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162956A1 (en) | 1997-04-07 | 2003-08-28 | Human Genome Sciences, Inc. | Leukocyte regulatory factors 1 and 2 |
| DE60037970T2 (de) * | 1999-06-28 | 2008-08-21 | Inter-K Pty. Ltd., Newcastle | Verfahren zur modulierung von integrin-vermittelter zellaktivitaet und hierfuer geeignete reagenzien |
| JP2003535832A (ja) * | 2000-06-09 | 2003-12-02 | ブリカス，テニ | ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化 |
| US6696546B1 (en) * | 2000-11-06 | 2004-02-24 | The Trustees Of Columbia University In The City Of New York | Peptide that kills growing but not stationary cells |
| AUPR230500A0 (en) | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
| AU2002240892A1 (en) * | 2001-01-02 | 2002-07-16 | Centre National De La Recherche Scientifique | Protein-protein interactions in adipocyte cells |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| CA2463631C (en) | 2001-10-15 | 2012-07-03 | Engeneic Gene Therapy Pty Limited | Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
| EP1451578B1 (en) * | 2001-11-16 | 2013-08-21 | Genentech, Inc. | Use of angptl3 antagonists for the treatment of liver diseases |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| EP1636385A4 (en) | 2003-06-24 | 2010-06-02 | Mirus Bio Corp | INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS |
| EP1684795A4 (en) * | 2003-10-17 | 2009-07-29 | Inter K Pty Ltd | METHODS AND AGENTS FOR THE TREATMENT OF CANCER |
| WO2005105837A2 (en) * | 2004-04-14 | 2005-11-10 | Brigham And Women's Hospital, Inc. | Use of the ribosomal protein rpl41 to treat infections and inhibit cancer |
| US20060194319A1 (en) | 2004-09-02 | 2006-08-31 | Webb Carol F | Promoter substitution for immunoglobulin therapy |
| WO2006029981A1 (en) | 2004-09-13 | 2006-03-23 | Vib Vzw | Abin-mediated protection against lung inflammatory disease |
| ATE470454T1 (de) | 2004-09-13 | 2010-06-15 | Genzyme Corp | Multimere konstrukte |
| WO2006031996A2 (en) | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| US7912214B2 (en) | 2007-07-20 | 2011-03-22 | Amadeus S.A.S. | Method and system for generating and controlling the distribution and use of personal promotion codes by targeted customers |
| WO2009103127A1 (en) * | 2008-02-22 | 2009-08-27 | Inter-K Pty Limited | Therapeutic peptides |
| EP2254592B1 (en) * | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| WO2010039778A2 (en) * | 2008-09-30 | 2010-04-08 | Zirus, Inc. | Mammalian genes involved in infection |
| EP2398484A4 (en) * | 2009-02-23 | 2013-07-10 | Inter K Pty Ltd | Inhibition of multiple cell activation signals |
-
2013
- 2013-01-24 CA CA2862485A patent/CA2862485C/en active Active
- 2013-01-24 CN CN201380016372.7A patent/CN104271590B/zh active Active
- 2013-01-24 AU AU2013202137A patent/AU2013202137B2/en active Active
- 2013-01-24 JP JP2014553578A patent/JP6249447B2/ja not_active Expired - Fee Related
- 2013-01-24 US US14/374,245 patent/US9403877B2/en active Active
- 2013-01-24 WO PCT/AU2013/000045 patent/WO2013110120A1/en not_active Ceased
- 2013-01-24 EP EP13740583.3A patent/EP2807180B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510393A5 (enExample) | ||
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| ES2869901T3 (es) | Agentes inmunosupresores y su uso en terapia | |
| JP2015518818A5 (enExample) | ||
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| JP2017537611A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2012176978A5 (enExample) | ||
| JP2011528895A5 (enExample) | ||
| JP2010506826A5 (enExample) | ||
| EP2583976A3 (en) | Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| JP2017532343A5 (enExample) | ||
| US20160263187A1 (en) | Use of mks inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
| JP2014529399A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| JP2011528897A5 (enExample) | ||
| JP2017529326A5 (enExample) | ||
| NZ708990A (en) | Method for activating helper t cell | |
| BR112013006088A2 (pt) | Construto de entrega isolado, e, composição farmacêuticapolinucleotídeo que encodifica um construtor de entrega, vetor de expressão, e célula hospedeira isolada" | |
| BR112012013139A2 (pt) | oligopeptídeos imp-3 e vacinas incluindo os mesmos | |
| JP2018023397A5 (enExample) | ||
| RU2018142174A (ru) | Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения |